COVID-19 and androgen-targeted therapy for prostate cancer patients.
Endocr Relat Cancer
; 27(9): R281-R292, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-577793
ABSTRACT
The current pandemic (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global health challenge with active development of antiviral drugs and vaccines seeking to reduce its significant disease burden. Early reports have confirmed that transmembrane serine protease 2 (TMPRSS2) and angiotensin converting enzyme 2 (ACE2) are critical targets of SARS-CoV-2 that facilitate viral entry into host cells. TMPRSS2 and ACE2 are expressed in multiple human tissues beyond the lung including the testes where predisposition to SARS-CoV-2 infection may exist. TMPRSS2 is an androgen-responsive gene and its fusion represents one of the most frequent alterations in prostate cancer. Androgen suppression by androgen deprivation therapy and androgen receptor signaling inhibitors form the foundation of prostate cancer treatment. In this review, we highlight the growing evidence in support of androgen regulation of TMPRSS2 and ACE2 and the potential clinical implications of using androgen suppression to downregulate TMPRSS2 to target SARS-CoV-2. We also discuss the future directions and controversies that need to be addressed in order to establish the viability of targeting TMPRSS2 and/or ACE2 through androgen signaling regulation for COVID-19 treatment, particularly its relevance in the context of prostate cancer management.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Prostatic Neoplasms
/
Coronavirus Infections
/
Betacoronavirus
/
Androgen Antagonists
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
/
Male
Language:
English
Journal:
Endocr Relat Cancer
Journal subject:
Endocrinology
/
Neoplasms
Year:
2020
Document Type:
Article
Affiliation country:
ERC-20-0165
Similar
MEDLINE
...
LILACS
LIS